Advertisement
Research ArticleCELLULAR AND MOLECULAR

Human Liver-Specific Organic Anion Transporter, LST-1, Mediates Uptake of Pravastatin by Human Hepatocytes

Daisuke Nakai, Rie Nakagomi, Yoshitake Furuta, Taro Tokui, Takaaki Abe, Toshihiko Ikeda and Kenji Nishimura
Journal of Pharmacology and Experimental Therapeutics June 2001, 297 (3) 861-867;

Abstract

Involvement of LST-1 (a human liver-specific transporter, also called OATP2) as the major transporter in the uptake of pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, by human liver was demonstrated. The hepatic uptake of pravastatin evaluated using human hepatocytes was Na+-independent and reached saturation with a Michaelis constant (Km) of 11.5 ± 2.2 μM. The uptake of pravastatin was temperature-dependent and was inhibited by estradiol-17β-d-glucuronide, taurocholic acid, bromosulfophthalein, and simvastatin acid, but not byp-aminohippurate. Estradiol-17β-d-glucuronide competitively inhibited pravastatin uptake with an inhibition constant comparable to theKm value for estradiol-17β-d-glucuronide transport, indicating that a common transporter mediates the transport of pravastatin and estradiol-17β-d-glucuronide in human hepatocytes. The results obtained with human hepatocytes agreed with those obtained with LST-1 expressing Xenopus oocytes. Oocytes microinjected with human liver polyadenylated mRNA showed Na+-independent uptake of pravastatin and estradiol-17β-d-glucuronide. A simultaneous injection of LST-1 antisense oligonucleotides completely abolished this uptake. Expression of LST-1 was immunohistochemically demonstrated in the human hepatocytes, but not in Hep G2 cells, which showed very low uptake of pravastatin. Therefore, LST-1 was regarded as a key molecule for pravastatin in liver-specific inhibition of cholesterol synthesis, making pravastatin accessible to the target enzyme, which would otherwise not be inhibited by this hydrophilic drug.

Pravastatin, a water-soluble 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has been shown to inhibit cholesterol synthesis in vivo specifically in the liver (Koga et al., 1986; Tsujita et al., 1990), which is the major site of cholesterol synthesis. Since the adverse effects of HMG-CoA reductase inhibitors during long-term treatment seem to depend in part upon the degree to which they act in extrahepatic tissues (Scott et al., 1989), the inhibitory effect on this enzyme restricted to the liver tissue is pharmacologically and toxicologically of great interest. Pravastatin is reported to be taken up by the liver efficiently through some kind of transport system (Hamelin and Turgeon, 1998), causing liver-specific inhibition of cholesterol synthesis in vivo. Furthermore, due to the hydrophilic nature of pravastatin, it is present only in low levels in other tissues and organs (Hamelin and Turgeon, 1998). This hydrophilicity causes low cellular uptake of pravastatin, as seen by the lack of inhibition of HMG-CoA reductase activity by pravastatin in Hep G2 cells (Cohen et al., 1993), the human hepatoma cell line, in which the hepatic transport activity for pravastatin is absent (Ziegler et al., 1994). These results indicate the importance of the hepatic transport system for pravastatin to exert its liver-specific pharmacological effect.

The hepatic transport system in the basolateral membrane is responsible for the clearance of various endogenous and exogenous substances from the systemic circulation (Meier, 1988; Tiribelli et al., 1990). The uptake of anionic compounds is mediated by Na+-dependent and Na+-independent systems (Berk et al., 1987;Tiribelli et al., 1990). Na+-taurocholic acid cotransporting polypeptides cloned from rat (Hagenbuch et al., 1991) and human (Hagenbuch and Meier, 1994) mediate the uptake of bile acids in a Na+-dependent manner. In addition to the Na+-dependent transport system, taurocholic acid is also transported via a Na+-independent carrier, a so-called multispecific anion transporter. This Na+-independent system transports a broad spectrum of substrates, including steroid conjugates, cardiac glycosides, and other xenobiotics (Müller and Jansen, 1997).

Previously, we demonstrated that pravastatin is taken up actively by rat hepatocytes through a Na+-independent multispecific anion transporter (Komai et al., 1992; Yamazaki et al., 1993) and that cloned organic anion transporting polypeptide 2 (oatp2) is the transporter responsible for the active hepatocellular uptake of pravastatin in rats (Abe et al., 1998; Tokui et al., 1999). A previous study of inhibition of sterol synthesis using various human cells suggested that pravastatin is also taken up by human hepatocytes via liver-specific transporter(s) (van Vliet et al., 1995). However, the uptake characteristics of pravastatin by human hepatocytes have not been investigated yet.

Recently, we also isolated a novel human liver-specific organic anion transporter, LST-1, which transports a wide variety of endogenous and exogenous anionic compounds into hepatocytes and is expressed exclusively in the liver (Abe et al., 1999). LST-1 has a moderate sequence homology to both the organic anion transporter polypeptide family and the prostaglandin transporter. The overall amino acid sequence homology is 42.2% with human OATP (Kullak-Ublick et al., 1995) and 34.9% with human prostaglandin transporter (Lu et al., 1996). LST-1 transports taurocholic acid, conjugated steroids (dehydroepiandrosterone sulfate, estradiol-17β-d-glucuronide, and estrone-sulfate), eicosanoids (prostaglandin E2, thromboxane B2, leukotriene C4, and leukotriene E4), and thyroid hormones in a Na+-independent manner, which demonstrates its multispecificity (Abe et al., 1999). As the hepatic expression level of human OATP is negligible (Abe et al., 1999), transport by LST-1 is believed to be the principal mechanism for Na+-independent clearance of bile acids and organic anions in the human liver. Hsiang et al. (1999) also reported the identical transporter to be OATP2 and the pravastatin transport by OATP2 expressed in 293c18 cells. König et al. (2000) also demonstrated by immunohistochemistry that LST-1 (OATP2) was localized to the basolateral membrane of human hepatocytes. However, whether LST-1 was the major transporter in the hepatocellular uptake of pravastatin in humans was still unclear.

To estimate the involvement of LST-1 in pravastatin transport in human liver, we investigated the uptake characteristics of pravastatin using human hepatocytes, Xenopus oocytes injected with human liver polyadenylated mRNA or cRNA derived from LST-1, and Hep G2 cells.

Experimental Procedures

Materials.

[14C]Pravastatin (specific activity: 14.3 mCi/mmol) and [3H]pravastatin (specific activity: 44.6 Ci/mmol) were synthesized at Amersham Japan (Tokyo, Japan). The radiochemical purity of [14C]pravastatin and [3H]pravastatin, determined by high performance liquid chromatography, was 99 and 96%, respectively. [3H]Estradiol-17β-d-glucuronide and [3H]taurocholic acid were purchased from NEN Life Science Products (Boston, MA). Simvastatin acid was synthesized at Sankyo (Tokyo, Japan). Cryopreserved human hepatocytes were purchased from In Vitro Technology (Baltimore, MD) and Tissue Transformation Technologies (Edison, NJ). Hep G2 cells were purchased from American Type Culture Collection (Rockville, MD). Percoll was purchased from Amersham Pharmacia Biotech (Uppsala, Sweden). Polyadenylated mRNA from human liver was purchased from Clontech Laboratories (Palo Alto, CA). Antisense oligonucleotides against LST-1 were synthesized at Amersham Japan (Tokyo, Japan). All other chemicals used were of reagent grade.

Animals.

Mature Xenopus laevis females were purchased from Hamamatsu Kyozai (Hamamatsu, Japan) and maintained in a controlled environment (Goldin, 1992). All experiments usingXenopus laevis were approved by the Ethical Committee of Sankyo for Animal Experiments.

Uptake Experiments.

Cryopreserved human hepatocytes were thawed and added into an L-15 medium. After centrifugation (50g, 3 min), nonviable cells were removed by Percoll density centrifugation (100g, 10 min) (Groothuis et al., 1995). The viable cells were suspended in Krebs-Henseleit buffer (pH 7.4) containing 118 mM NaCl, 5 mM KCl, 1.1 mM MgSO4, 2.5 mM CaCl2, 1.2 mM KH2PO4, 25 mM NaHCO3, 10 mM glucose, and 10 mM HEPES, saturated with O2/CO2 (95/5). Viability of the cells was verified by the Trypan Blue exclusion test, and the cells with >90% viability were used. The cell suspension was preincubated at 37°C for 5 min. Then, the radiolabeled compounds were added to start the uptake experiment. At designated times, the incubation mixture was centrifuged, and the cells were transferred through a silicone oil layer to the alkaline solution layer, which thus terminated the uptake reaction (Yamazaki et al., 1993). After the cells were solubilized in the alkaline layer, the bottom of the tube containing the solubilized cell layer was sliced off with a razor blade and transferred into a vial for liquid scintillation counting. After addition of 10 ml of scintillation fluid (Hionic Fluor, Packard Bioscience, Groningen, The Netherlands) to the vial, the radioactivity was determined using a Packard TriCarb 2200 CA liquid scintillation analyzer. To examine whether pravastatin uptake by the human hepatocytes was sodium-dependent, cells were incubated with a choline buffer. The composition of the choline buffer was the same as that of the Krebs-Henseleit buffer, except that NaCl and NaHCO3 were replaced with choline chloride and choline bicarbonate, respectively. Hep G2 cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal calf serum, 1 mM pyruvate, and penicillin/streptomycin (100 U/100 μg/ml). Approximately 105 Hep G2 cells were seeded in a 24-well plate 24 h before the uptake study. The cells were then washed with prewarmed, serum-free medium, and uptake studies were performed. The cells were incubated with a radiolabeled compound in a CO2 incubator for 1 h, washed with ice-cold phosphate-buffered saline, and lysed with 0.1 N NaOH. After solubilization, the radioactivity was determined using a Packard TriCarb 2200 CA liquid scintillation analyzer (Packard Instrument, Meriden, CT). Protein concentrations were determined using a commercially available protein assay kit (Bio-Rad, Richmond, CA).

Expression of LST-1 in Xenopus laevisOocytes.

In vitro synthesis of LST-1-cRNA was performed using the cloned cDNA of LST-1, as described previously (Abe et al., 1999).Xenopus laevis oocytes were prepared according to a procedure described previously (Tokui et al., 1999). The oocytes were injected with 50 ng of polyadenylated human liver mRNA, with 50 ng of transcribed cRNA of LST-1, or with the same volume of water for the control. After injection, the oocytes were cultured for 3 days at 18°C, with daily replacements of the modified Barth's solution (88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.3 mM Ca(NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4, and 15 mM HEPES, pH 7.6). Hybrid-depletion experiments were performed using antisense oligonucleotides of LST-1 (5′-TTGATTTTGGTCCAT-3′, position 1–15). Fifty nanograms of polyadenylated human liver mRNA was incubated for 15 min at 42°C with 5.0 μg antisense oligonucleotides of LST-1. Samples were then cooled on ice and injected into oocytes.

Uptake by Oocytes.

Uptake experiments were started by incubating the oocytes at room temperature in 100 μl of either the sodium-free or sodium-containing uptake buffer (100 mM choline chloride or NaCl, respectively, with 10 mM HEPES/5 mM Tris, pH 7.5, 1 mM KCl, 1 mM CaCl2, and 2 mM MgCl2). At the indicated intervals, uptake was terminated by the addition of 3 ml of ice-cold incubation buffer, and the oocytes were washed three times with the same ice-cold buffer. The water-injected oocytes were used as the control. A single oocyte was solubilized in 0.5 ml of 10% (w/w) sodium dodecyl sulfate, and 4 ml of scintillation fluid (Pico Fluor, Packard Bioscience) was added. The radioactivity was determined using a Packard TriCarb 2200 CA liquid scintillation analyzer.

Preparation of Rabbit Antibodies against Human LST-1.

A peptide containing 12 amino acids (CNLDMQDNAAAN, position 691–702) at the carboxy-terminus of human LST-1 was synthesized and linked to maleimide-activated keyhole limpet hemocyanin (KHL; Pierce, Rockford, IL). The KHL-linked peptide (1 mg/injection) was emulsified by mixing with an equal volume of Freund's adjuvant and injected into the foot pads of female rabbits. Booster injections were performed at 2, 6, and 8 weeks, and the animals were sacrificed at 10 weeks. The antibodies were affinity-purified using CNBr-activated Sepharose CL-4B (Amersham Pharmacia Biotech, Uppsala, Sweden) coupled with synthetic peptides according to a standard procedure (Shigemoto et al., 1994).

Immunohistochemistry.

Air-dried smears of human hepatocytes and Hep G2 cells were fixed for 10 min in 10% formaldehyde in phosphate-buffered saline and permeabilized by one cycle of freeze-thawing. Treated cells were incubated with the antibody raised against LST-1 (diluted in DAKO Antibody Diluent, DAKO, Carpinteria, CA) for 60 min at room temperature. Immunostaining was performed using a commercially available immunostaining kit (Nichirei, Tokyo, Japan). Nuclei were stained with hematoxylin after the immunostaining.

Determination of Kinetic Parameters.

The kinetic parameters for pravastatin uptake were calculated according to the following equation:V0=Vmax·S/(Km+S)+Pdif·S Equation 1where V0 is the initial uptake rate (pmol/min/106 cells),Vmax is the maximum uptake rate (pmol/min/106 cells),Km is the Michaelis constant (μM),Pdif is the nonspecific uptake clearance (μl/min/106 cells), and Sis the pravastatin concentration in the medium (μM). The data collected in the uptake experiments were fitted to the above equation by an iterative nonlinear least-squares method using WinNonlin (version 1.1, Scientific Consulting, Inc., Cary, NC). The apparent kinetic parameters (Km app,Vmax app, andPdif app) for pravastatin uptake in the presence of estradiol-17β-d-glucuronide were also estimated by fitting the data to eq. 1. TheVmax app and Pdif app values for pravastatin thus obtained were practically the same as those in the absence of estradiol-17β-d-glucuronide, whereas theKm app value was increased with the addition of estradiol-17β-d-glucuronide. Thus, the inhibition constant (Ki) was calculated according to the following equation, assuming competitive inhibition:Ki=Km·i/(Km app−Km) Equation 2where Km is the Michaelis constant for pravastatin uptake in the absence of estradiol-17β-d-glucuronide (μM),Km app is the Michaelis constant for pravastatin uptake in the presence of estradiol-17β-d-glucuronide (μM) andi is the estradiol-17β-d-glucuronide concentration in the medium (μM). The LST-1-mediated uptake rate of pravastatin was calculated by subtracting the uptake in water-injected oocytes from that in LST-1 cRNA-injected oocytes. The kinetic parameters were calculated according to the following equation:V0=Vmax·S/(Km+S) Equation 3where V0 is the initial uptake rate (pmol/min/106 cells),Vmax is the maximum uptake rate (pmol/min/oocyte), Km is the Michaelis constant (μM), and S is the pravastatin concentration in the medium (μM). The uptake data were fitted to the above equation by an iterative nonlinear least-squares method using WinNonlin (version 1.1, Scientific Consulting, Inc.). All obtained kinetic parameters are shown as mean ± S.E.

Results

Uptake of [14C]Pravastatin, [3H]Estradiol-17β-d-glucuronide, and [3H]Taurocholic Acid by Human Hepatocytes.

The time course of uptake of [14C]pravastatin (10 μM), [3H]estradiol-17β-d-glucuronide (10 μM), and [3H]taurocholic acid (10 μM) by human hepatocytes is shown in Fig. 1. Pravastatin uptake increased linearly up to at least 5 min. The uptake of estradiol-17β-d-glucuronide and taurocholic acid increased linearly up to 120 s. Thus, the initial uptake rate was calculated by linear regression using the six data points collected between 0.5 and 5 min for pravastatin and between 20 and 120 s for estradiol-17β-d-glucuronide and taurocholic acid.

Figure 1
Figure 1

Time course of the uptake of [14C]pravastatin (10 μM) (A), [3H]estradiol-17β-d-glucuronide (10 μM) (B), and [3H]taurocholic acid (10 μM) (C) by human hepatocytes. Data show one representative result of three independent uptake measurements.

The uptake of [14C]pravastatin, [3H]estradiol-17β-d-glucuronide, and [3H]taurocholic acid became saturated with increasing concentrations of the substrate in the medium (Fig.2). The kinetic parameters of pravastatin, estradiol-17β-d-glucuronide, and taurocholic acid were 11.5 ± 2.2 μM (n = 3), 14.0 ± 6.5 μM (n = 3), and 25.5 ± 5.0 μM (n = 3), respectively, forKm; 10.2 ± 2.6 pmol/min/106 cells (n = 3), 59.3 ± 38.9 pmol/min/106 cells (n = 3), and 77.0 ± 25.3 pmol/min/106 cells (n = 3), respectively, for Vmax; and 0.30 ± 0.14 μl/min/106 cells (n = 3), 0.23 ± 0.06 μl/min/106 cells (n = 3), and 0.16 ± 0.08 μl/min/106 cells (n = 3), respectively, for Pdif.

Figure 2
Figure 2

Concentration dependence of the uptake of [14C]pravastatin (A), [3H]estradiol-17β-d-glucuronide (B), and [3H]taurocholic acid (C) by human hepatocytes. Each compound was incubated in a concentration range of 1 to 100 μM. Data show one representative result of three independent uptake measurements. The solid line represents the least-squares fit of the data to eq. 1.

The uptake of [14C]pravastatin and [3H]estradiol-17β-d-glucuronide was Na+-independent as shown in Table1. On the other hand, taurocholic acid uptake showed Na+ dependence (Table 1). The fraction of Na+-independent taurocholic acid uptake was 20% of the total uptake (n = 3). The pravastatin uptake exhibited a remarkable temperature dependence, decreasing to 20.0 ± 4.8% at 0°C, compared with that at 37°C (n = 3).

View this table:
Table 1

Effect of ion substitution on initial uptake rate of [14C]pravastatin (10 μM), [3H]estradiol-17β-d-glucuronide (10 μM), and [3H]taurocholic acid (10 μM) by human hepatocytes

To characterize the pravastatin uptake by human hepatocytes, the effect of organic anions on the uptake of [14C]pravastatin was examined. The uptake of pravastatin was inhibited by taurocholic acid, simvastatin acid, and bromosulfophthalein, but not by p-aminohippurate, a substrate for renal organic anion exchanger OAT1 (Sekine et al., 1997) as shown in Table 2. In the presence of estradiol-17β-d-glucuronide (20 μM), the apparent Km of pravastatin increased by 2.6 times, compared with the Km in the absence of estradiol-17β-d-glucuronide. However, the apparent Vmax andPdif values did not change significantly. This result demonstrates that estradiol-17β-d-glucuronide competitively inhibits the uptake of pravastatin. According to eq. 2, theKi of estradiol-17β-d-glucuronide in inhibiting pravastatin uptake was calculated to be 13.9 ± 4.0 μM (n = 3).

View this table:
Table 2

Effects of organic anions (300 μM) on initial uptake rate of [14C]pravastatin (10 μM) by human hepatocytes and on uptake of [14C]pravastatin (30 μM) by LST-1 cRNA-injected oocytes

Uptake of [14C or 3H]Pravastatin and [3H]Estradiol-17β-d-glucuronide inXenopus laevis Oocytes.

The uptake of [14C]pravastatin and [3H]estradiol-17β-d-glucuronide by LST-1 cRNA-injected oocytes was 5.9 and 5.2 times higher than that of water-injected control oocytes, respectively. The replacement of sodium in the medium by choline did not affect the pravastatin or estradiol-17β-d-glucuronide uptake (data not shown). The LST-1-mediated [14C]pravastatin and [3H]estradiol-17β-d-glucuronide uptake became saturated with a Km of 13.7 ± 4.0 μM (n = 3) and 9.7 ± 2.0 μM (n = 3), respectively, as shown in Fig. 4. The LST-1-mediated uptake of pravastatin was inhibited by taurocholic acid, simvastatin acid, and bromosulfophthalein, but not byp-aminohippurate (Table 2). Oocytes, microinjected with human liver polyadenylated mRNA, showed Na+-independent uptake of [3H]pravastatin and [3H]estradiol-17β-d-glucuronide (Table 3). The simultaneous injection of antisense oligodeoxynucleotides of LST-1 completely inhibited the uptake of [3H]pravastatin and [3H]estradiol-17β-d-glucuronide, leading to uptake levels similar to those in the water-injected oocytes (Table 3).

Figure 4
Figure 4

Concentration dependence of the uptake of [14C]pravastatin (A) and [3H]estradiol-17β-d-glucuronide (B) in oocytes injected with LST-1 cRNA. ▪, LST-1 cRNA-injected oocytes. ●, water-injected oocytes. Uptake was measured in the medium containing sodium chloride (see Experimental Procedures). Data are expressed as the mean ± S.E. of three to seven uptake measurements in one representative preparation of three separate oocyte preparations. The solid line represents the least-squares fit of the data to eq. 3.

View this table:
Table 3

Effect of ion substitution and LST-1 antisense inhibition of the uptake of [3H]pravastatin (2.21 μM) and [3H]estradiol-17β-d-glucuronide (0.76 μM) in oocytes injected with human liver polyadenylated mRNA

Uptake of [14C]Pravastatin and [3H]Estradiol-17β-d-glucuronide in Hep G2 Cells and Immunohistochemistry of LST-1 in Human Hepatocytes and Hep G2 Cells.

The uptake of pravastatin and estradiol-17β-d-glucuronide by Hep G2 cells was linear up to a substrate concentration of 150 μM (Fig. 5). Immunohistochemical analysis demonstrated no immunoreactivity of Hep G2 cells to LST-1 in contrast to the significant immunoreactivity of the human hepatocytes (Fig. 6).

Figure 5
Figure 5

Concentration dependence of the uptake of pravastatin (▪) and estradiol-17β-d-glucuronide (●) by Hep G2 cells. Data are expressed as the mean ± S.E. of three uptake measurements.

Figure 6
Figure 6

Immunohistochemical staining of LST-1 in human hepatocytes (A) and Hep G2 (B). Magnification, 200×. Scale bar, 20 μm.

Discussion

The active transport of pravastatin by human hepatocytes has been demonstrated in the present study. In the human hepatocytes, the uptake of pravastatin became saturated with increasing pravastatin concentrations (Fig. 2), and was Na+-independent (Table 1) and temperature-dependent. This indicates that pravastatin uptake by human hepatocytes is a transporter-mediated and energy-requiring process. The uptake of pravastatin was inhibited by estradiol-17β-d-glucuronide, taurocholic acid, simvastatin acid, and bromosulfophthalein, but not byp-aminohippurate (Table 2). All these characteristics of pravastatin uptake by human hepatocytes were in good agreement with those by rat hepatocytes (Yamazaki et al., 1993). However, theVmax value for pravastatin was about 30 times lower in the human hepatocytes than in the rat hepatocytes (Yamazaki et al., 1993), suggesting lower transporter activity in humans than in rats and/or a decrease in the transporter activity of human hepatocytes after cryopreservation (De Loecker et al., 1990).

In the same manner as above, the uptake of estradiol-17β-d-glucuronide and taurocholic acid by human hepatocytes became saturated with increasing substrate concentrations (Fig. 2). The uptake of estradiol-17β-d-glucuronide was Na+-independent, whereas that of taurocholic acid was Na+-dependent (Table 1). TheKm values were 25.5 ± 5.0 μM for taurocholic acid (Fig. 2), which was lower than the values reported previously (Azer and Stacy, 1993: 45.7 μM; Sandker et al., 1994: 62 μM) and was 14.6 ± 6.5 μM for estradiol-17β-d-glucuronide (Fig. 2). This is the first observation and report for Na+-independent uptake of estradiol-17β-d-glucuronide by human hepatocytes. The kinetic analysis demonstrates that estradiol-17β-d-glucuronide competitively inhibits pravastatin uptake by human hepatocytes (Fig.3). TheKi value of estradiol-17β-d-glucuronide in the inhibition of the pravastatin uptake was comparable to theKm value for the hepatocellular uptake of estradiol-17β-d-glucuronide, suggesting that a common transporter is responsible for the uptake of both pravastatin and estradiol-17β-d-glucuronide.

Figure 3
Figure 3

Eadie-Hofstee plots of [14C]pravastatin uptake in the absence (▪) and presence (●) of estradiol-17β-d-glucuronide (20 μM). Data show one representative result of three independent uptake measurements. The solid lines were obtained by calculation according to the equation for enzyme kinetics. Kinetic parameters thus obtained are as follows:Km, 10.0 ± 4.1 μM;Vmax, 6.22 ± 1.88 pmol/min/106 cells; and Pdif, 0.07 ± 0.02 μl/min/106 cells for the control experiment; Km app, 25.9 ± 5.0 μM;Vmax app, 4.97 ± 1.84 pmol/min/106 cells; and Pdif app, 0.05 ± 0.01 μl/min/106 cells for the inhibition experiment by estradiol-17β-d-glucuronide.

Oocytes expressing LST-1 showed essentially the same characteristics of pravastatin uptake as those observed in human hepatocytes. The uptake of both [14C]pravastatin and [3H]estradiol-17β-d-glucuronide in LST-1 cRNA-injected oocytes was Na+-independent and became saturated with increasing concentrations (Fig. 4). TheKm values were 13.7 ± 4.0 μM for pravastatin and 9.7 ± 2.0 μM for estradiol-17β-d-glucuronide, which were comparable to those obtained from the uptake study using human hepatocytes. The inhibitory effects of organic anions on pravastatin uptake in the LST-1-expressing oocytes were also similar to those in the human hepatocytes (Table 2).

Our hybrid-depletion study demonstrates that the uptake of pravastatin and estradiol-17β-d-glucuronide by the human liver is via LST-1. The Na+-independent uptake of [3H]pravastatin and [3H]estradiol-17β-d-glucuronide was observed in oocytes microinjected with human liver polyadenylated RNA, as well as in human hepatocytes (Tables 1 and 3). The LST-1 antisense oligonucleotide completely abolished the Na+-independent uptake of [3H]pravastatin and [3H]estradiol-17β-d-glucuronide into the oocytes (Table 3). Thus, LST-1 plays a predominant role in the uptake of pravastatin and estradiol-17β-d-glucuronide in this experimental system. Because the contribution of transporters, which are not expressed in oocytes microinjected with human liver polyadenylated RNA, cannot be ruled out, further studies, for example, an inhibition study using an LST-1 transporter activity neutralizing antibody, may need to be performed.

A previous in vitro study on HMG-CoA reductase inhibition (Cohen et al., 1993) suggests the importance of LST-1 for the pharmacological action of pravastatin in the target cells. In Hep G2 cells, a frequently used cell model of human hepatocytes, the inhibitory effect of pravastatin on the cholesterol synthesis was much less potent than those of other lipophilic HMG-CoA reductase inhibitors, simvastatin and lovastatin, although, in the cell homogenates, the inhibitory effects of the three inhibitors were very similar (Cohen et al., 1993). In contrast, in primary cultured human hepatocytes, the inhibitory effect of pravastatin was comparable to that of simvastatin (Cohen et al., 1993). Hep G2 cells were immunohistochemically demonstrated to express no LST-1, and failed to show saturable uptake at increasing concentrations of pravastatin or estradiol-17β-d-glucuronide (Figs.5 and 6). Their uptake by Hep G2 cells was considered to proceed by simple, passive diffusion. These clearly indicated that the transporter system by LST-1 made pravastatin accessible to the HMG-CoA reductase, which would otherwise not be inhibited by this hydrophilic molecule.

In conclusion, LST-1 has been demonstrated to be involved as the major transporter in active, Na+-independent uptake of pravastatin by human hepatocytes. Furthermore, since cells that do not express LST-1 showed no inhibitory effect of HMG-CoA reductase by pravastatin, we conclude that LST-1 is the key molecule for the liver-specific inhibition of cholesterol synthesis by pravastatin in humans.

Acknowledgments

We thank Dr. K. Fukuda for helpful suggestions in the immunohistochemical study.

Footnotes

  • Send reprint requests to: Dr. Taro Tokui, Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co., Ltd., 2-58 Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan. E-mail:tokuit{at}shina.sankyo.co.jp

  • Abbreviations:
    HMG-CoA
    3-hydroxy-3-methylglutaryl coenzyme A
    OATP2
    organic anion transporting polypeptide 2
    LST-1
    human liver-specific organic anion transporter
    KHL
    keyhole limpet hemocyanin
    Km
    Michaelis constant
    Vmax
    maximum uptake rate
    Pdif
    nonspecific uptake clearance
    Ki
    inhibition constant
    • Received October 19, 2000.
    • Accepted January 2, 2001.

References

  1. ↵
    1. Abe T,
    2. Kakyo M,
    3. Sakagami H,
    4. Tokui T,
    5. Nishio T,
    6. Tanemoto M,
    7. Nomura H,
    8. Hebert SC,
    9. Matsuno S,
    10. Kondo H,
    11. et al.
    (1998) Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholic acid, and comparison with oatp2. J Biol Chem 273:22395–22401.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Abe T,
    2. Kakyo M,
    3. Tokui T,
    4. Nakagomi R,
    5. Nakai D,
    6. Nomura H,
    7. Unno M,
    8. Suzuki M,
    9. Naitoh T,
    10. Matsuno S,
    11. et al.
    (1999) Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 274:17159–17163.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Azer SA,
    2. Stacy NH
    (1993) Differential effects of cyclosporin A on the transport of bile acids by human hepatocytes. Biochem Pharmacol 46:813–819.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Berk PD,
    2. Potter BJ,
    3. Stremmel W
    (1987) Role of plasma membrane ligand-binding proteins in the hepatocellular uptake of albumin-bound organic anions. Hepatology 7:165–176.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Cohen LH,
    2. van Vliet A,
    3. Roodenburg L,
    4. Jansen LMC,
    5. Griffioen M
    (1993) Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase. Biochem Pharmacol 45:2203–2208.
    OpenUrlCrossRefPubMed
  6. ↵
    1. De Loecker R,
    2. Fuller BJ,
    3. Gruwez J,
    4. De Loecker W
    (1990) The effects of cryopreservation on membrane integrity, membrane transport, and protein synthesis in rat hepatocytes. Cryobiology 27:143–152.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Goldin A
    (1992) Maintenance of Xenopus laevis and oocyte injection. Methods Enzymol 207:266–279.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Groothuis GMM,
    2. Sandker GW,
    3. Prium J,
    4. Weert B,
    5. Slooff MJH,
    6. Meijer DKF
    (1995) Comparison of human hepatocytes isolated from livers accepted or discarded for orthotopic transplantation. Toxicol In Vitro 9:951–958.
    OpenUrlPubMed
  9. ↵
    1. Hagenbuch B,
    2. Meier PJ
    (1994) Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest 93:1326–1331.
  10. ↵
    1. Hagenbuch B,
    2. Stieger B,
    3. Foguet M,
    4. Lubbert H,
    5. Meier PJ
    (1991) Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proc Natl Acad Sci USA 88:10629–10633.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Hamelin BA,
    2. Turgeon J
    (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19:26–37.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Hsiang B,
    2. Zhu Y,
    3. Wang Z,
    4. Wu Y,
    5. Sasseville V,
    6. Yang WP,
    7. Kirchgessner TG
    (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). J Biol Chem 274:37161–37168.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Koga T,
    2. Shimada Y,
    3. Kuroda M,
    4. Tsujita Y,
    5. Hasegawa K,
    6. Yamazaki M
    (1986) Tissue selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 877:50–60.
    OpenUrlPubMed
  14. ↵
    1. Komai T,
    2. Shigehara E,
    3. Tokui T,
    4. Koga T,
    5. Ishigami M,
    6. Kuroiwa C,
    7. Horiuchi S
    (1992) Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem Pharmacol 43:667–670.
    OpenUrlCrossRefPubMed
  15. ↵
    1. König J,
    2. Cui Y,
    3. Nies AT,
    4. Keppler D
    (2000) A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol 278:G156–G164.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Kullak-Ublick GA,
    2. Hagenbuch B,
    3. Stieger B,
    4. Schteingart CD,
    5. Hofmann AF,
    6. Wolkoff AW,
    7. Meier PJ
    (1995) Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 109:1274–1282.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Lu R,
    2. Kanai N,
    3. Bao Y,
    4. Schuster V
    (1996) Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA (hPGT). J Clin Invest 98:1142–1149.
    OpenUrlPubMed
  18. ↵
    1. Meier PJ
    (1988) Transport polarity of hepatocytes. Semin Liver Dis 8:649–661.
  19. ↵
    1. Müller M,
    2. Jansen PL
    (1997) Molecular aspects of hepatobiliary transport. Am J Physiol 272:G1285–G1303.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Sandker GW,
    2. Weert B,
    3. Olinga P,
    4. Wolters H,
    5. Slooff MJH,
    6. Meijer DKF,
    7. Groothuis GMM
    (1994) Characterization of transport in isolated human hepatocytes. Biochem Pharmacol 47:2193–2000.
    OpenUrlCrossRefPubMed
  21. ↵
    1. LaRosa JC
    1. Scott WA,
    2. Mahoney EM,
    3. Mosley ST
    (1989) Mechanism of action and differential pharmacology of pravastatin, a hydrophilic and selective HMG-CoA reductase inhibitor. in New Advances in the Control of Lipid Metabolism: Focus on Pravastatin, ed LaRosa JC (Royal Society of Medicine, London), pp 1–8.
  22. ↵
    1. Sekine T,
    2. Watanabe N,
    3. Hosoyamada M,
    4. Kanai Y,
    5. Endou H
    (1997) Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem 272:18526–18529.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Shigemoto R,
    2. Abe T,
    3. Nomura S,
    4. Nakanishi S,
    5. Hirano T
    (1994) Antibodies inactivating mGluR1 metabotropic glutamate receptor block long-term depression in cultured Purkinje cells. Neuron 12:1245–1255.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Tiribelli C,
    2. Lunazzi GC,
    3. Sottocasa GL
    (1990) Biochemical and molecular aspects of the hepatic uptake of organic anions. Biochim Biophys Acta 1031:261–275.
    OpenUrlPubMed
  25. ↵
    1. Tokui T,
    2. Nakai D,
    3. Nakagomi R,
    4. Yawo H,
    5. Abe T,
    6. Sugiyama Y
    (1999) Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharm Res 16:904–908.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Tsujita Y,
    2. Kuroda M,
    3. Shimada Y,
    4. Tanzawa K,
    5. Arai M,
    6. Kaneko I,
    7. Tanaka M,
    8. Masuda H,
    9. Tamura C,
    10. Watanabe Y
    (1990) CS-514, a competitive inhibitor of 3-hydroxyl-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta 1045:115–120.
    OpenUrlPubMed
  27. ↵
    1. van Vliet AK,
    2. van Thiel GCF,
    3. Huisman RH,
    4. Moshage H,
    5. Yap SH,
    6. Cohen LH
    (1995) Different effects of 3-hydroxyl-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim Biophys Acta 1254:105–111.
    OpenUrlPubMed
  28. ↵
    1. Yamazaki M,
    2. Suzuki H,
    3. Hanano M,
    4. Tokui T,
    5. Komai T,
    6. Sugiyama Y
    (1993) Na+-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 264:G36–G44.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Ziegler K,
    2. Blumrich M,
    3. Hummelsiep S
    (1994) The transporter for the HMG-CoA reductase inhibitor pravastatin is not present in Hep G2 cells. Evidence for the nonidentity of the carrier for pravastatin and certain transport for BSP. Biochim Biophys Acta 1223:195–201.
    OpenUrlPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleCELLULAR AND MOLECULAR

Human Liver-Specific Organic Anion Transporter, LST-1, Mediates Uptake of Pravastatin by Human Hepatocytes

Daisuke Nakai, Rie Nakagomi, Yoshitake Furuta, Taro Tokui, Takaaki Abe, Toshihiko Ikeda and Kenji Nishimura
Journal of Pharmacology and Experimental Therapeutics June 1, 2001, 297 (3) 861-867;
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement